Login to Your Account

Topical HDAC Inhibitor Could 'Shape' CTCL Care

By Marie Powers
Staff Writer

Thursday, April 4, 2013
Shape Pharmaceuticals Inc. is not aiming to reshape the industry. The Cambridge, Mass.-based biotech has the more modest goal of advancing its single asset, topical histone deacetylase (HDAC) inhibitor SHP-141, in cutaneous T-cell lymphoma (CTCL) and, potentially, other inflammatory skin conditions.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription